Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$27.00-20.70%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · ARQT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-11-05.
The screen ranks ARQT against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
• ZORYVE net product sales for the third quarter of 2026 were $143.9 million, reflecting 45% year-over-year growth and an 11% sequential increase versus the second quarter of 2026 .
Stated in 3 of 3 supplied quarters. Management reported: “• ZORYVE net product sales for the third quarter of 2026 were $143.9 million, reflecting 45% year-over-year growth and an 11% sequential increase versus the second quarter of 2026 .” “Financial Guidance • The Company raised net product sales guidance for the full year 2026 to $535 million–$545 million from $525 million–$540 million.” Revenue was $143.919 million in 2026-Q3.
“• ZORYVE net product sales for the third quarter of 2026 were $143.9 million, reflecting 45% year-over-year growth and an 11% sequential increase versus the second quarter of 2026 .”
“• ZORYVE net product sales for the second quarter of 2026 were $129.9 million, reflecting 59% year-over-year growth and a 23% sequential increase versus the first quarter of 2026 .”
“• ZORYVE net product sales for the first quarter of 2026 were $105.4 million, reflecting a 17% sequential decline versus the fourth quarter of 2025 and 65% year-over-year growth .”
• The FDA has set a target action date of February 23, 2027, for the supplemental New Drug Application to expand the indication for ZORYVE cream 0.05% for mild to moderate atopic dermatitis to infant…
Stated in 3 of 3 supplied quarters. Management reported: “• The FDA has set a target action date of February 23, 2027, for the supplemental New Drug Application to expand the indication for ZORYVE cream 0.05% for mild to moderate atopic dermatitis to infants aged 3 to 24 months.” “• The Company remains on track to disclose topline results from the Phase 2 proof-of-concept study of ZORYVE foam 0.3% for the treatment of vitiligo and share its decision on program advancement by the end of 2026.”
• Sustained positive cash flow, generating $18.9 million of cash flow from operating activities in the third quarter of 2026.
Stated in 3 of 3 supplied quarters. Management reported: “• Sustained positive cash flow, generating $18.9 million of cash flow from operating activities in the third quarter of 2026.” “• Sustained positive cash flow, generating $12.6 million of cash flow from operating activities in the second quarter of 2026.” Operating cash flow was $2.239 million in 2026-Q1.
“• Sustained positive cash flow, generating $18.9 million of cash flow from operating activities in the third quarter of 2026.”
The year-over-year increase was driven by greater marketing spend primarily in support of the Skin to Believe In celebrity awareness campaign and by increased personnel-related expenses resulting fro…
Stated in 3 of 3 supplied quarters. Management reported: “The year-over-year increase was driven by greater marketing spend primarily in support of the Skin to Believe In celebrity awareness campaign and by increased personnel-related expenses resulting from the dermatology sales force expansion and launch of the primary care provider and pediatric sales team.” “• Completed hiring of a targeted sales team dedicated to primary care and pediatric healthcare providers with the launch into the field anticipated by the end of August.”
Continue strong growth of ZORYVE net product sales and raise full-year 2026 net product sales guidance to $525 million to $540 million.
Over the trailing year it converted 0.84x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
5 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.
“• The FDA has set a target action date of February 23, 2027, for the supplemental New Drug Application to expand the indication for ZORYVE cream 0.05% for mild to moderate atopic dermatitis to infant…”
“• The FDA accepted an sNDA for ZORYVE cream 0.05% to expand the indication for the treatment of mild to moderate atopic dermatitis in infants aged 3 to 24 months with a Prescription Drug User Fee Act…”
“Clinical and Regulatory Developments • Submitted an sNDA for ZORYVE cream 0.05% to the FDA to expand the indication for the treatment of mild to moderate atopic dermatitis in infants ages 3 to 24 mon…”
“• Sustained positive cash flow, generating $12.6 million of cash flow from operating activities in the second quarter of 2026.”
“• Sustained positive cash flow, generating $2.2 million of positive cash flow from operating activities in Q1 2026.”
“The year-over-year increase was driven by greater marketing spend primarily in support of the Skin to Believe In celebrity awareness campaign and by increased personnel-related expenses resulting fro…”
“• Completed hiring of a targeted sales team dedicated to primary care and pediatric healthcare providers with the launch into the field anticipated by the end of August.”
“• The dermatology sales force expansion has been completed, with representatives in the field at the beginning of May, to optimize prescriber targeting and call frequency in order to deepen adoption…”